| Effect | Decrease |
| Trial Design | Cohort |
| Trial Length | 6+ Months |
| Number of Subjects | 30 |
| Sex | Both Genders |
In patients with bipolar disorder given between 600-800mcg chromium daily, it seemed that a minority of persons reported less depressive symptoms after three weeks (30% response as assessed by HAMD, 39% as assessed by MADRS) with no apparent benefit reported for manic symptoms nor any longer term benefits being reported due to dropouts.
No placebo control used in this study.
